Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Rigel Pharmaceuticals, Inc. at current levels.
A profitable small-cap biotech trading at 2x earnings because the market refuses to believe the numbers are real.
Where RIGL is headed
Rigel in mid-2028 looks nothing like the perpetually-diluting biotech investors filed under 'avoid' for a decade. Three commercial drugs (TAVALISSE for chronic ITP, REZLIDHIA for IDH1-mutant AML, GAVRETO for RET-fusion cancers) are throwing off cash. Free cash flow just crossed $79M on a $745M market cap. Operating margin sits above 20%. This is a biotech that acts like a specialty pharma, and the market is still pricing it like a burn-rate story from 2019.
Read the full Compass Direction on RIGL
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $39.04).
See the full RIGL analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Rigel Pharmaceuticals, Inc. at current levels. A profitable small-cap biotech trading at 2x earnings because the market refuses to believe the numbers are real.
What is RIGL's Compass Score?
Rigel Pharmaceuticals, Inc. scores 76/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for RIGL?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the RIGL page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.